Late relapses in Hodgkin's disease.

Provencio-Pulla, Mariano; Sanchez, A.; Cantos, Blanca; Blesa, J. Gasent; Méndez, María José; Maximiano, Constanza; Cubedo, Ricardo; Bonilla, Félix; Galán, Lucía; Huelves, Miriam

doi:10.1200/jco.2010.28.15_suppl.e18537

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Earlier studies have chosen a cut‐off for late relapse at two, 7 three, 6,8,9 four 10 or five 4,5,11–15 years after initial diagnosis, or after completion of first‐line treatment. In the most recent literature, the cut‐off for LR has been five years with an incidence of 3%–5.6% 13,15,16 …”

Section: Introductionmentioning

confidence: 99%

“…In the most recent literature, the cut-off for LR has been five years with an incidence of 3%-5.6%. 13,15,16 While the International Prognostic Score (IPS) and interim-positron emission topography/computed topography (PET/CT)-scan are used for risk stratification and treatment guidance, no predictive factors for late relapse have yet been identified. 4,7,9,10,13,15 Late relapse is also poorly characterized with regard to clinical characteristics, underlying biology and therapeutic approaches.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry

Andersen

Hamilton-Dutoit

Modvig³

et al. 2022

Br J Haematol

View full text Add to dashboard Cite

Summary We analysed a large cohort of Hodgkin lymphoma (HL) patients in order to characterize: (1) the pattern of late recurrence of lymphoid malignancies (LR) after initial treatment for HL over a 35‐year period; (2) the clinicopathological parameters influencing the risk of LR; and (3) the outcome of patients experiencing LR. We reviewed data of 3350 HL patients diagnosed in Denmark between 1982 and 2018 and registered in the Danish National Lymphoma Registry (LYFO). LR was defined as a recurrence of lymphoid malignancy at least five years after initial diagnosis. LR occurred in 58 patients, with a cumulative incidence at 10, 15 and 20 years of 2.7%, 4.0% and 5.4% respectively. LR was more frequently observed in patients with nodular lymphocyte‐predominant HL (NLPHL) [hazard ratio (HR) 4.5; 95% confidence interval (CI): 2.4–8.4, p < 0.001]. In classical HL (cHL) patients, older age and lymphocytopenia were risk factors for LR with HRs of 1.04 per additional year (95% CI: 1.02–1.06) and 5.6 (95% CI: 2.7–11.5) respectively. Mixed cellularity histological subtype was a risk factor for LR, but only in females, with a HR of 5.4 (95% CI: 1.4–20.4, p = 0.014). In contrast to what was observed in NLPHL, LR in cHL was associated with an almost threefold increased risk of death compared with patients in continuous complete remission. Approximately one fifth (22.4%) of patients with LR experienced a second relapse.

show abstract